Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: A population study using 75 maternal-cord plasma samples

British Journal of Clinical Pharmacology

Volumn 64, Issue 5, 2007, Pages 634-644

  Hirt, Déborah ^a,g   Urien, Saïk ^a,f   Jullien, Vincent ^a,b   Firtion, Ghislaine ^c   Chappuy, Hélène ^a,d   Rey, Elisabeth ^a,b   Pons, Gérard ^a,b   Mandelbrot, Laurent ^e   Treluyer, Jean Marc ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b INSERM   (France)

^c Gynécologie Obstétrique Hôpital Louis Mourier ^*  (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e HÔPITAL LOUIS MOURIER   (France)

^f CENTRE RENÉ HUGUENIN   (France)

^g HÔPITAL SAINT VINCENT DE PAUL   (France)

Author keywords

Cord plasma concentrations; HIV; Nelfinavir; NONMEM; Placental transfer

Indexed keywords

CLAZEPAM; DRUG METABOLITE; NELFINAVIR; RITONAVIR; SL 72469; UNCLASSIFIED DRUG;

ADULT; AMNION FLUID; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; DELIVERY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG ELIMINATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; MAJOR CLINICAL STUDY; MATERNAL PLASMA; PLACENTAL TRANSFER; POPULATION RESEARCH; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; UMBILICAL CORD BLOOD; VIRUS TRANSMISSION;

AMNIOTIC FLUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FETAL BLOOD; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; NELFINAVIR; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; TREATMENT OUTCOME;

EID: 35248871060     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.02885.x     Document Type: Article

References (38)

1. Pacifici GM. Transfer of antivirals across the human placenta. Early Hum Dev 2005 81 : 647 54.
2. Forestier F, de Renty P, Peytavin G, Dohin E, Farinotti R, Mandelbrot L. Maternal-fetal transfer of saquinavir studied in the ex vivo placental perfusion model. Am J Obstet Gynecol 2001 185 : 178 81.
3. Gavard L, Gil S, Peytavin G, Ceccaldi PF, Ferreira C, Farinotti R, Mandelbrot L. Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model. Am J Obstet Gynecol, 2006 195 : 296 301.
4. Sudhakaran S, Ghabrial H, Nation RL, Kong DC, Gude NM, Angus PW, Rayner CR. Differential bidirectional transfer of indinavir in the isolated perfused human placenta. Antimicrob Agents Chemother 2005 49 : 1023 8.
5. Chappuy H, Treluyer JM, Rey E, Dimet J, Fouche M, Firtion G, Pons G, Mandelbrot L. Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol 2004 191 : 558 62.
6. Marzolini C, Rudin C, Decosterd LA, Telenti A, Schreyer A, Biollaz J, Buclin T, Swiss Mother + Child HIV Cohort Study. Transplacental passage of protease inhibitors at delivery. AIDS 2002 16 : 889 93.
7. Mirochnick M, Dorenbaum A, Holland D, Cunningham-Schrader B, Cunningham C, Gelber R, Mofenson L, Culnane M, Connor J, Sullivan JL. Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr Infect Dis J 2002 21 : 835 8.
8. Gingelmaier A, Kurowski M, Kastner R, Eberle J, Mylonas I, Belohradsky BH, Friese K, Grubert TA. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS 2006 20 : 1737 43.
9. Viracept package insert. Agouron Pharmaceuticals, La Jolla, California.
10. Lillibridge JH, Lee CA, Pithavala YK. The role of CYP2C19 in the metabolism of nelfinavir mesylate. XII Annual Meeting and Exposition of the American Association of Pharmaceuticals Scientists, San Francisco, California, Abstract 3035, 1998.
11. Zhang KE, Wu E, Patick AK, Kerr B, Zorbas M, Lankford A, Kobayashi T, Maeda Y, Shetty B, Webber S. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrob Agents Chemother 2001 45 : 1086 93.
12. Parry E, Shields R, Turnbull A. Transit time in the small intestine in pregnancy. J Obstet Gynaecol Br Commonw 1970 77 : 900 1.
13. Krauer B, Krauer F, Hytten FE. Drug disposition and pharmacokinetics in the maternal-placental-fetal unit. Pharmacol Ther 1980 10 : 301 28.
14. Dean M, Stock B, Patterson RJ, Levy G. Serum protein binding of drugs during and after pregnancy in humans. Clin Pharmacol Ther 1980 28 : 253 61.
15. Loebstein R, Lalkin A, Koren G. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet 1997 33 : 328 43.
16. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998 101 : 289 94.
17. Young AM, Allen CE, Audus KL. Efflux transporters of the human placenta. Adv Drug Deliv Rev 2003 55 : 125 32.
18. Pellegrin I, Breilh D, Montestruc F, Caumont A, Garrigue I, Morlat P, Le Camus C, Saux MC, Fleury HJ, Pellegrin JL. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study). AIDS 2002 16 : 1331 40.
19. Burger DM, Bergshoeff AS, De Groot R, Gibb D, Walker S, Treluyer JM, Hoetelmans RM, PENTA 5 Study Group. Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children. J Pediatr 2004 145 : 403 5.
20. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, Berrebi A, Benifla JL, Burgard M, Lachassine E, Barret B, Chaix ML, Bongain A, Ciraru-Vigneron N, Crenn-Hebert C, Delfraissy JF, Rouzioux C, Mayaux MJ, Blanche S, Agence Nationale de Recherches sur le SIDA (ANRS) 075 Study Group. Lamivudine- zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001 285 : 2083 93.
21. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001 28 : 481 504.
22. Beal SL, Sheiner LB. NONMEM User's Guide; NONMEM Project Group. University of California, San Francisco, 1998.
23. Ihaka R, Gentleman RR. A language for data analysis and graphics. J Comput Graphic Statistics 1996 5 : 299.
24. Parke J, Holford NH, Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Meth Programs Biomed 1999 59 : 19 29.
25. Skowron G, Leoung G, Kerr B, Dusek A, Anderson R, Beebe S, Grosso R. Lack of pharmacokinetic interaction between nelfinavir and nevirapine. AIDS 1998 12 : 1243 4.
26. Lacroix I, Damase-Michel C, Lapeyre-Mestre M, Montastruc JL. Prescription of drugs during pregnancy in France. Lancet 2000 356 : 1735 6.
27. Charles B, Norris R, Xiao X, Hague W. Population pharmacokinetics of metformin in late pregnancy. Ther Drug Monit 2006 28 : 67 72.
28. Covington DL, Conner SD, Doi PA, Swinson J, Daniels EM. Risk of birth defects associated with nelfinavir exposure during pregnancy. Obstet Gynecol 2004 103 : 1181 9.
29. Hirt D, Urien S, Jullien V, Firtion G, Rey E, Pons G, Blanche S, Treluyer JM. Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children. Antimicrob Agents Chemother 2006 50 : 910 6.
30. Hirt D, Treluyer JM, Jullien V, Firtion G, Chappuy H, Rey E, Pons G, Mandelbrot L, Urien S. Pregnancy-related effects on nelfinavir and M8 pharmacokinetics: a population study in 133 women. Antimicrob Agents Chemother 2006 50 : 2079 86.
31. Panhard X, Goujard C, Legrand M, Taburet AM, Diquet B, Mentre F, COPHAR 1 ANRS Study Group. Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART. Br J Clin Pharmacol 2005 60 : 390 403.
32. Treluyer JM, Gueret G, Cheron G, Sonnier M, Cresteil T. Developmental expression of CYP2C and CYP2C-dependant activities in the human liver: in-vivo/in-vitro correlation and inducibility. Pharmacogenetics 1997 7 : 441 52.
33. van Heeswijk RP, Khaliq Y, Gallicano KD, Bourbeau M, Seguin I, Phillips EJ, Cameron DW. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum. Clin Pharmacol Ther 2004 76 : 588 97.
34. Villani P, Floridia M, Pirillo MF, Cusato M, Tamburrini E, Cavaliere AF, Guaraldi G, Vanzini C, Molinari A degli Antoni A, Regazzi M. Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women. Br J Clin Pharmacol 2006 62 : 309 15.
35. Nellen JF, Schillevoort I, Wit FW, Bergshoeff AS, Godfried MH, Boer K, Lange JM, Burger DM, Prins JM. Nelfinavir plasma concentrations are low during pregnancy. Clin Infect Dis 2004 39 : 736 40.
36. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 2005 44 : 989 1008.
37. Mathias AA, Maggio-Price L, Lai Y, Gupta A, Unadkat JD. Changes in pharmacokinetics of anti-HIV protease inhibitors during pregnancy. the role of CYP3A and P-glycoprotein. J Pharmacol Exp Ther 2006 316 : 1202 9.
38. Gil S, Saura R, Forestier F, Farinotti R. P-glycoprotein expression of the human placenta during pregnancy. Placenta Mar 2005 26 : 268 70.